Presentation is loading. Please wait.

Presentation is loading. Please wait.

Typhoid vaccination: A curtain raiser & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI 2011-13 August 24 th &

Published byMelvyn Hardy Modified over 9 years ago

Similar presentations

Presentation on theme: "Typhoid vaccination: A curtain raiser & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI 2011-13 August 24 th &"— Presentation transcript:

1 Typhoid vaccination: A curtain raiser & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI 2011-13 vipinipsita@gmail.com August 24 th & 25 th 2012 Mid-term Meeting of IAPCOI, The Hyatt Regency Hotel, Mumbai

2 Is typhoid indeed a serious public health problem in India to merit vaccination?

3 Crude typhoid fever incidence rates by region, 2000

4 Incidence rate of typhoid fever in Asia: comparison of 2 multi-centre trials

5 Incidence of Typhoid in India Kothari et al. The burden of enteric fever 259 J Infect Developing Countries 2008; 2(4): 253-259.

6 Age-specific incidence of culture-proven typhoid fever from population-based studies Bhan MKBhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005 2;366(9487):749-62.Bahl RBhatnagar SLancet.

7 Characteristics and incidence of typhoid fever from the study sites: Age group Ochiai RL, Acosta CJ, Danovaro-Holliday MC et al. (2008) A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ 86(4):260-68. SiteHechi, China Kolkata India North Jakarta Indonesia Karachi Pakistan Hue, Viet Nam Total Typhoid Incidence (per 100000/yr) by age 15.3214.281.7451.721.3107.6 0- 1 yearsNA89.20.0NA 21.6 2- 4 yearsNA340.1148.7573.2NA364.8 5- 15 years29.3493.5180.3412.924.2170.8 ≥ 16 years12.4119.751.2NA10.946.8

8 How big is the paratyphoid burden?

9 Trends in S. Paratyphi A, Safdarjung Hospital (S. Typhi vs. S. Paratyphi A) J Infect Dev Ctries 2010; 4(6):404-411.

10 Typhoid: Antibiotics resistance

11 Global distribution of antimicrobial resistance in S typhi (1990–2004)

12 Rates of Antibiotic Resistance among S. Typhi Isolates from Five Asian Study Sites in the DOMI Programme

13 Studies reporting high-level ciprofloxacin resistance in S. typhi & S. paratyphi A in India Harish BN, Menezes GA. Indian J Med Microbiol. 2011 Jul-Sep;29(3):223-9.

14 Typhoid fever: Our scenario

15 Mangla Hospital & Research Center  Bijnor a small city of western Uttar Pradesh, a northern state of India  District population (2007): 3.4 million  Decadal population growth (2007)= 27.16%; UP=25.8%, India=21.34%  Birth rate: 460 per 10,000; UP=382, India=268  Females ratio: 896 per 1000 males, UP=898; Inia=933  Delivery at hospitals/nursing homes: 28.7%; India= 40.7%

16 A sentinel site surveillance of 10 VPDs

17 Total OPD cases, March 2011-May 2012

18 * Till May 18, 2012 40.9% of all 10 VPDS!!

19 Age group of typhoid cases (N=382)

20 Immunization status (N=382)

21 Seasonal breakup: March 2011-May 2012

22 Arguments against significant typhoid burden in India

23 Non-believers!!!

24 Significance of Typhoid in India* 1. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull WHO 2008; 86: 260-268. *Mathew JL. Conjugate typhoid vaccine(s) in the Indian context. Indian Pediatr. 2009 Feb;46(2):182-4. Indian Pediatr.

25 Do we need typhoid vaccination?

26 Justification for Typhoid vaccination Problem - I Globally about 21.6 million cases every year, causing about 2.1 lac deaths But estimates indicate 33 million cases 90% of all cases and deaths in Asia, rest in Africa and Latin America Problem – II Multi drug resistance Problem – III Changing age scenario – infants and toddlers equally affected

27 Do we have ‘effective’ typhoid vaccine to issue recommendations on widespread use?

28 Orphan disease & Neglected vaccine!!

29 Vaccination against typhoid Evidence from Cuba, Iran, Thailand, Malaysia, Vietnam, & China confirms that a one-dose, Vi- PS vaccination strategy targeting a wide age range can effectively control disease However, only 6 countries currently have school or community-based typhoid vaccination programs

30

31 Vi-PS typhoid vaccine has shown effectiveness in India!! In a recently published cluster randomized effectiveness trial conducted in over 40,000 subjects in urban slums of Kolkata, the overall effectiveness of the vaccine at 2 years follow up was 61%, and in children below 5 years was 80% Interestingly the herd protection of 44% was noted in unvaccinated children in the vaccinated cluster as compared to the control cluster Dipika Sur, R. Leon Ochiai, et al. A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India. N Engl J Med 2009;361:335-44.

32 What about the currently available Indian Vi-PS conjugate vaccine? Does it have any role? Can we improve it further?

33

34 What is the pipeline for next generation typhoid vaccines?

35 Geographic Representation of Typhoid Vaccination Programs Despite recommendations, typhoid vaccines are significantly underutilized!!!

36 Barriers to widespread typhoid vaccine use: Other potential challenges: Paratyphi burden? Lack of WHO prequalified vaccines Country political will Managing typhoid as a communicable disease rather than within the immunization system Current focus on Hib, pneumococcal, and rotavirus vaccine introduction in GAVI countries

37 How can IAPCOI help in prevention of Typhoid fever in India? Can we initiate a collaborative project with international agencies/institutions? What level of support/commitment is required?

38 Thank You!

Download ppt "Typhoid vaccination: A curtain raiser & IAPCOI perspectives Vipin M. Vashishtha, MD, FIAP Convener, IAPCOI 2011-13 August 24 th &"

Similar presentations

HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.

HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Objective of EBR related to IAPCOI 19 th February 2012, IMA House, New Delhi Vipin M. Vashishtha, MD, FIAP Convener, 2011-13

Objective of EBR related to IAPCOI 19 th February 2012, IMA House, New Delhi Vipin M. Vashishtha, MD, FIAP Convener,
Rotavirus vaccine impact. Introduction. Rotavirus vaccines lead to significant reductions in severe and fatal diarrhea in both vaccinated and unvaccinated.

Rotavirus vaccine impact. Introduction. Rotavirus vaccines lead to significant reductions in severe and fatal diarrhea in both vaccinated and unvaccinated.
Burden of Rotavirus Disease & Impact of Rotavirus Vaccination Umesh D. Parashar, MBBS, MPH Lead, Viral Gastroenteritis Epidemiology Team Centers for Disease.

Burden of Rotavirus Disease & Impact of Rotavirus Vaccination Umesh D. Parashar, MBBS, MPH Lead, Viral Gastroenteritis Epidemiology Team Centers for Disease.
Update on Vaccines not Included in this Tender: Rotavirus Vaccines Pre Tender Meeting UNICEF Supply Division, 10-11th December 2008 Ann Ottosen.

Update on Vaccines not Included in this Tender: Rotavirus Vaccines Pre Tender Meeting UNICEF Supply Division, 10-11th December 2008 Ann Ottosen.
1 Global AIDS Epidemic The first AIDS case was diagnosed in 1981 20 years later, 20 million people are dead and 37.8 million people (range: 34.6–42.3 million)

1 Global AIDS Epidemic The first AIDS case was diagnosed in years later, 20 million people are dead and 37.8 million people (range: 34.6–42.3 million)
DENGUE: EPIDEMIOLOGY PART 1

DENGUE: EPIDEMIOLOGY PART 1
Introduction of New vaccines Hib as an Example St. Petersburg 25-27 Jun 2001.

Introduction of New vaccines Hib as an Example St. Petersburg Jun 2001.
Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.

Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.
The challenge of non-communicable disease in our near neighbours: a disease burden perspective Professor Alan Lopez School of Population Health The University.

The challenge of non-communicable disease in our near neighbours: a disease burden perspective Professor Alan Lopez School of Population Health The University.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.

U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
Tuberculosis in Children and Young Adults

Tuberculosis in Children and Young Adults
GLOBAL TB PROGRAMME Knut Lönnroth Global TB Programme, WHO Monitoring social protection Sickness insurance Food package Disability grants Other welfare.

GLOBAL TB PROGRAMME Knut Lönnroth Global TB Programme, WHO Monitoring social protection Sickness insurance Food package Disability grants Other welfare.
2,100,000 Number of pregnant women with HIV/AIDS 200,000Number of pregnant women receiving PMTCT 630,000Number of MTCT new infections 2,000,000Number of.

2,100,000 Number of pregnant women with HIV/AIDS 200,000Number of pregnant women receiving PMTCT 630,000Number of MTCT new infections 2,000,000Number of.
Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.

Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.
Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.

Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.
Global Immunization Performance Update through 2011.

Global Immunization Performance Update through 2011.
Child deaths: Causes and epidemiological dimensions Robert E. Black, M.D., M.P.H. Johns Hopkins Bloomberg School of Public Health.

Child deaths: Causes and epidemiological dimensions Robert E. Black, M.D., M.P.H. Johns Hopkins Bloomberg School of Public Health.
Low Birth Weight: The Indian Perspective Prof. H.P.S. Sachdev.

Low Birth Weight: The Indian Perspective Prof. H.P.S. Sachdev.
Regional Overview of Progress on Universal Access in Asia-Pacific Steve Kraus, Regional Director UNAIDS Regional Support Team for Asia and the Pacific.

Regional Overview of Progress on Universal Access in Asia-Pacific Steve Kraus, Regional Director UNAIDS Regional Support Team for Asia and the Pacific.

Similar presentations

Ads by Google